TY - JOUR
T1 - Rational Design of Photochromic Analogues of Tricyclic Drugs
AU - Riefolo, Fabio
AU - Sortino, Rosalba
AU - Matera, Carlo
AU - Claro, Enrique
AU - Preda, Beatrice
AU - Vitiello, Simone
AU - Traserra, Sara
AU - Jiménez, Marcel
AU - Gorostiza, Pau
N1 - Funding Information:
This project has received funding from European Union Research and Innovation Programme Horizon 2020 (Human Brain Project SGA2 Grant Agreement 785907 and SGA3 No. 945539), DEEPER (Grant No. 101016787), ERASynBio programme (Modulightor project funded by Ministry of Economy and Competitiveness, Grant No. PCIN-2015-163-C02-02), and financial support from Generalitat de Catalunya through the Agency for Management of University and Research Grants (Grant No. 2017-SGR-1442), the General Directorate for Research (Grant No. IU16- 011593, co-funded with FEDER Operational Program of Catalonia 2014–2020) and CERCA Programme; Ministry of Science and Innovation/FEDER (Grants CTQ2016-80066-R, PID2019-111493RB-I00, SAF2017-88019-C3-1-R), and “La Caixa” Foundation (Grant No. LCF/PR/HR19/52160010).
Publisher Copyright:
© 2021 American Chemical Society.
PY - 2021/7/8
Y1 - 2021/7/8
N2 - Tricyclic chemical structures are the core of many important drugs targeting all neurotransmitter pathways. These medicines enable effective therapies to treat from peptic ulcer disease to psychiatric disorders. However, when administered systemically, they cause serious adverse effects that limit their use. To obtain localized and on-demand pharmacological action using light, we have designed photoisomerizable ligands based on azobenzene that mimic the tricyclic chemical structure and display reversibly controlled activity. Pseudo-analogues of the tricyclic antagonist pirenzepine demonstrate that this is an effective strategy in muscarinic acetylcholine receptors, showing stronger inhibition upon illumination both in vitro and in cardiac atria ex vivo. Despite the applied chemical modifications to make pirenzepine derivatives sensitive to light stimuli, the most potent candidate of the set, cryptozepine-2, maintained a moderate but promising M1 vs M2 subtype selectivity. These photoswitchable "crypto-azologs"of tricyclic drugs might open a general way to spatiotemporally target their therapeutic action while reducing their systemic toxicity and adverse effects.
AB - Tricyclic chemical structures are the core of many important drugs targeting all neurotransmitter pathways. These medicines enable effective therapies to treat from peptic ulcer disease to psychiatric disorders. However, when administered systemically, they cause serious adverse effects that limit their use. To obtain localized and on-demand pharmacological action using light, we have designed photoisomerizable ligands based on azobenzene that mimic the tricyclic chemical structure and display reversibly controlled activity. Pseudo-analogues of the tricyclic antagonist pirenzepine demonstrate that this is an effective strategy in muscarinic acetylcholine receptors, showing stronger inhibition upon illumination both in vitro and in cardiac atria ex vivo. Despite the applied chemical modifications to make pirenzepine derivatives sensitive to light stimuli, the most potent candidate of the set, cryptozepine-2, maintained a moderate but promising M1 vs M2 subtype selectivity. These photoswitchable "crypto-azologs"of tricyclic drugs might open a general way to spatiotemporally target their therapeutic action while reducing their systemic toxicity and adverse effects.
UR - http://www.scopus.com/inward/record.url?scp=85110236648&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.1c00504
DO - 10.1021/acs.jmedchem.1c00504
M3 - Article
C2 - 34160229
AN - SCOPUS:85110236648
SN - 0022-2623
VL - 64
SP - 9259
EP - 9270
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 13
ER -